EN
DE
Home
About us
Biofronteras Expertise
Management and supervisory board
Product Pipeline
Clinical trials
Products
Product Portfolio
Investors
Key stock information
Financial reports
Financial announcements
Shareholder structure
Corporate calendar
Corporate governance
Annual general meeting
SEC reporting
FAQs Delisting BFRA
Takeover Offer of Deutsche Balaton AG
Presentations & contact
Career
Careers
Contact
Biofrontera
Investors
Financial announcements
Corporate News
Corporate News
01/18/2023 11:50
PTA-News: Biofrontera AG: Start of Phase 3 Clinical Trial in the US for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
01/12/2023 11:30
PTA-News: Biofrontera AG: Biofrontera receives notice of allowance for US patent on innovative photodynamic treatment protocol
01/06/2023 08:25
PTA-News: Biofrontera AG: Court Rules 2021 Executive Board and Supervisory Board Resolutions Concerning IPO of Biofrontera Inc. To Be Unlawful
Corporate News archive
2022
2022
12/19/2022 14:05
PTA-News: Biofrontera AG: Commercial launch of Ameluz® in Finland
12/08/2022 13:55
PTA-News: Biofrontera AG: Biofrontera establishes UK subsidiary to strengthen its sales activities in the country
11/23/2022 15:00
PTA-News: Biofrontera AG: Biofrontera reports on business development in the third quarter and the first nine months of 2022
11/16/2022 12:35
PTA-News: Biofrontera AG: Biofrontera AG strengthens international marketing and sales activities
10/26/2022 08:40
PTA-News: Biofrontera AG: Subscription offer for up to 7,089,673 new shares begins on October 28, 2022
09/06/2022 09:50
PTA-News: Biofrontera AG: Biofrontera AG obtains notice of allowance for U.S. patent on nanoemulsion formulation
08/25/2022 10:30
PTA-News: Biofrontera AG: Annual General Meeting of Biofrontera AG appoints Prof. Dr. Karin Lergenmüller as a member of the Supervisory Board
08/19/2022 19:50
PTA-News: Biofrontera AG: Biofrontera extends appointment of Management Board member Paul Böckmann
08/18/2022 21:20
PTA-News: Biofrontera AG: Biofrontera reports financial results for the six months ended June 30, 2022
08/10/2022 14:00
PTA-News: Biofrontera AG: The request to convene an extraordinary shareholders' meeting by Maruho is not complied with
08/05/2022 11:30
PTA-News: Biofrontera AG: Maruho Deutschland GmbH demands convening of an extraordinary general meeting
08/03/2022 10:30
PTA-News: Biofrontera AG: Employees appeal in own statement to the shareholders not to accept the takeover offer of Deutsche Balaton AG
07/29/2022 21:00
PTA-News: Biofrontera AG: Management Board and Supervisory Board jointly recommend not to accept the takeover offer of Deutsche Balaton AG
07/21/2022 16:25
PTA-News: Biofrontera AG: Biofrontera AG will publish statement on takeover offer by Deutsche Balaton AG shortly
07/13/2022 14:55
PTA-News: Biofrontera AG: Biofrontera obtains notice of allowance for Australian patent on innovative PDT treatment protocol
06/08/2022 14:15
PTA-News: Biofrontera AG: Biofrontera's license partner Louis Widmer receives an extension of its marketing authorization for Ameluz®
05/17/2022 16:20
PTA-News: Biofrontera AG: Biofrontera reports results for the first quarter of 2022
05/13/2022 18:20
PTA-News: Biofrontera AG: First quarter conference call to be held on May 19, 2022
04/30/2022 08:30
PTA-News: Biofrontera AG: Biofrontera reports results for the fiscal year 2021
04/28/2022 11:35
PTA-News: Biofrontera AG: Biofrontera shifts the publication of the Annual Report 2021 to April 29, 2022
04/14/2022 14:20
PTA-News: Biofrontera AG: Biofrontera announces conference call to be held on April 29, 2022 to discuss fiscal year 2021 financial results
04/04/2022 14:35
PTA-News: Biofrontera AG: Governmental price decree for Ameluz® withdrawn in Spain
04/04/2022 12:05
PTA-News: Biofrontera AG: Statement of Biofrontera AG on the open letter of Maruho Deutschland GmbH dated March 31, 2022
03/14/2022 12:30
PTA-News: Biofrontera AG: Biofrontera improves the brand protection of Ameluz®-PDT in the US and strengthens internal quality assurance structures
03/09/2022 22:45
PTA-News: Biofrontera AG: Biofrontera files Form 15F to suspend SEC Reporting Requirements and starts trading Level I ADS program on US OTC market
02/01/2022 14:30
PTA-News: Biofrontera AG: Biofrontera AG announces progress of phase III study for the treatment of sBCC with Ameluz®
2021
2021
12/14/2021 17:15
PTA-News: Biofrontera AG: Biofrontera AG announces results of the elections for the new Supervisory Board
12/13/2021 15:05
PTA-News: Biofrontera AG: Biofrontera enrolls first patient to phase IIb clinical study evaluating Ameluz® / BF-RhodoLED® for acne
12/08/2021 13:25
PTA-News: Biofrontera AG: Biofrontera AG obtains notice of allowance for US patent on PDT-lamp and treatment method
12/06/2021 12:50
PTA-News: Biofrontera AG: Biofrontera enrolls first patient to phase I safety study evaluating photodynamic therapy with three tubes of Ameluz®
12/02/2021 14:40
PTA-News: Biofrontera AG: Biofrontera obtains notice of allowance for US patent on innovative illumination protocol
11/17/2021 23:01
PTA-News: Biofrontera AG: Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021
11/16/2021 14:55
PTA-News: Biofrontera AG: Biofrontera AG announces initiation of clinical studies
11/09/2021 11:40
PTA-News: Biofrontera AG: Conference call to discuss third quarter 2021 financial results to be held on November 18, 2021
11/02/2021 20:10
PTA-News: Biofrontera AG: Biofrontera is setting the path for further expansion in the U.S. with the IPO of its US subsidiary Biofrontera Inc.
10/01/2021 13:40
PTA-News: Biofrontera AG: Biofrontera reports preliminary approximate revenues for the month of September 2021
09/08/2021 18:10
PTA-News: Biofrontera AG: Biofrontera reports preliminary revenue for the month of August 2021
08/19/2021 17:45
PTA-News: Biofrontera AG: Biofrontera reports financial results for the six months ended June 30, 2021
08/12/2021 14:55
PTA-News: Biofrontera AG: Conference call to discuss half-year 2021 financial results to be held on August 20, 2021
08/09/2021 15:00
PTA-News: Biofrontera AG: Biofrontera reports preliminary revenue for the month of July 2021
07/23/2021 10:15
PTA-News: Biofrontera AG: Biofrontera enters into license and supply agreement with Medac for the marketing of Ameluz® in Poland
07/06/2021 16:00
PTA-News: Biofrontera AG: Biofrontera reports preliminary revenue for the month of June 2021
06/22/2021 15:00
PTA-News: Biofrontera AG: Biofrontera provides update on clinical developments
06/07/2021 15:50
PTA-News: Biofrontera AG: Biofrontera reports preliminary revenue for the month of May 2021
05/11/2021 16:35
PTA-News: Biofrontera AG: Biofrontera reports Q1 2021 financial results
05/06/2021 12:50
PTA-News: Biofrontera AG: Biofrontera reports preliminary revenue for the month of April 2021
05/03/2021 15:40
PTA-News: Biofrontera AG: First quarter conference call to be held on May 12, 2021
04/12/2021 19:40
PTA-News: Biofrontera AG: Biofrontera reports results for the 2020 financial year
04/08/2021 16:30
PTA-News: Biofrontera AG: Biofrontera announces preliminary revenue for Q1 2021
03/31/2021 16:00
PTA-News: Biofrontera AG: Biofrontera announces conference call to be held on April 13, 2021 to discuss fiscal year 2020 financial results
03/31/2021 09:40
PTA-News: Biofrontera AG: Biofrontera submits application for FDA approval of new BF-RhodoLED® XL lamp
02/26/2021 15:20
PTA-News: Biofrontera AG: Biofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24.7 million
02/25/2021 15:35
PTA-News: Biofrontera AG: Biofrontera AG announces entry of capital increase into the commercial register
02/24/2021 14:30
PTA-News: Biofrontera AG: Biofrontera submits study report of pharmacokinetics study to FDA
02/02/2021 16:35
PTA-News: Biofrontera AG: Ludwig Lutter appointed new Chief Financial Officer effective March 1, 2021
Corporate News PDF Archive
2020 (Text messages)
2020 (Text messages)
12/07/2020 15:10
PTA-News: Biofrontera AG: Biofrontera enters into a license and supply agreement with Galenica AB for the marketing of Ameluz® in Scandinavia
11/11/2020 13:00
PTA-News: Biofrontera AG: Biofrontera reports third quarter and first nine months 2020 results
11/02/2020 14:00
PTA-News: Biofrontera AG: Biofrontera announces conference call to be held on November 12, 2020 to discuss Q3 2020 financial results
10/14/2020 10:30
PTA-News: Biofrontera AG: Receives reasons from the German Federal Court of Justice for overturning ruling of the Cologne Higher Regional Court
10/08/2020 17:00
PTA-News: Biofrontera AG: Biofrontera AG reports completion of the clinical phase of the pharmacokinetics study
09/22/2020 17:50
PTA-News: Biofrontera AG: German Federal Supreme Court overturns ruling of the Cologne Higher Regional Court
09/09/2020 14:00
PTA-News: Biofrontera AG: Biofrontera AG to participate in two upcoming conferences
08/26/2020 15:40
PTA-News: Biofrontera AG: Biofrontera report results for the first six months of 2020
08/20/2020 19:00
PTA-News: Biofrontera AG: Admission to trading of Biofrontera's 1.00% qualified subordinated mandatory convertible bond 2020/2021
08/19/2020 10:30
PTA-News: Biofrontera AG: Biofrontera announces conference call to be held on August 27, 2020 to discuss half-year 2020 financial results
08/18/2020 11:00
PTA-News: Biofrontera AG: Capital measure oversubscribed: Placement of the 1.00% qualified subordinated mandatory convertible bond 2020/2021
07/23/2020 14:30
PTA-News: Biofrontera AG: Supervisory Board of Biofrontera AG renews Management Board appointment
06/30/2020 14:39
PTA-News: Biofrontera AG: Biofrontera confirms financing need
05/28/2020 17:35
PTA-News: Biofrontera AG: Results of the 2020 Annual General Meeting of Biofrontera AG
05/19/2020 16:15
PTA-News: Biofrontera AG: Biofrontera reports Q1 2020 financial results
05/13/2020 10:00
PTA-News: Biofrontera AG: Biofrontera dismisses case against DUSA Pharmaceuticals, Inc. in California state court
05/12/2020 17:00
PTA-News: Biofrontera AG: Biofrontera announces conference call to be held on May 20, 2020 to discuss first quarter 2020 financial results
2020
2020
20200420_Biofrontera_2019_Earnings_Release_EN_final.pdf
20200417_Q1_2020_prelim_revenue_EN_final.pdf
20200409_YE_con_call_details_EN_final.pdf
20200320_Covid_19_measures_EN_final.pdf
20200310_label_extension_EU-EN_final.pdf
20200219_update_clinical_developments_EN_final.pdf
20200203_EMA_positive_opinion_EN_final.pdf
20200131_restructuring_and_Duenwald_EN_final.pdf
20200114_follow_up_results_periphery_EN_final.pdf
20200106_reorganisation_Inc_EN_final.pdf
2019
2019
190711_PM HV 2019_EN_v2_final.pdf
(235 KB)
190724_PM Ergebnis Erwerbsangebote_EN_v2_final.pdf
(186 KB)
2019.03.25_BFRA corporate update_EN_v4_final.pdf
(276 KB)
2019.03.27_PM_Aufsichtsrat_EN_v2_final.pdf
(184 KB)
2019.04.02_Maruho Angebot Info_EN_v2_final.pdf
(184 KB)
2019.04.15_Q1 2019 prelim revenue_EN_v3_final.pdf
(230 KB)
2019.04.16_con call details_EN_v1_final.pdf
(167 KB)
2019.04.16_Studienergebnisse sekundäre Endpunkte_EN_v3_final.pdf
(235 KB)
2019.04.25_PM Einberufung HV_EN_v2_final.pdf
(203 KB)
2019.04.29_2018 Earnings Release_EN_v8_final.pdf
(234 KB)
2019.05.16_con call details_EN_v1_final.pdf
(180 KB)
2019.05.29_Biofrontera 1Q19 Earnings Release_EN_v8_final.pdf
(256 KB)
2019.06.04_Nominierung AR_EN_v1_final.pdf
(180 KB)
2019.06.12_RJ and JMP Conference_EN_v1_final.pdf
(180 KB)
2019.06.21_PM Angebot Maruho_EN_final.pdf
(186 KB)
2019.07.08_HJ1 2019 prelim revenue_EN_v2_final.pdf
(227 KB)
2019.08.05_PM_corporate update CLS integration_EN_v6_final.pdf
(185 KB)
2019.08.14_con call details_EN_v1_final.pdf
(179 KB)
2019.09.17_Antrag EMA_EN_v3_final.pdf
(183 KB)
2019.09.17_Baader Investment Conference_EN_v1_final.pdf
(176 KB)
2019.10.23_Fall Clinical_DE_v4_final.pdf
(101 KB)
2019.11.06_con call details_EN_final.pdf
(186 KB)
20190108_PM_upscaling batch size_EN_final.pdf
(285 KB)
20190211_PM_Arzneimittel-Schutzrichtlinie_EN_final.pdf
(130 KB)
20190225_PR_SteveAwards_EN_final.pdf
(132 KB)
20190701_PM Angebot Balaton_EN.pdf
(88 KB)
20190827_H1 2019 Earnings Release_EN_v3_final.pdf
(208 KB)
20191122_conference participation_EN_v1_final.pdf
(198 KB)
20191213_CCO BF Inc._EN_final.pdf
(188 KB)
20191220_aoHV Ergebnis_EN_final.pdf
(203 KB)
2018
2018
20181227_PR_Dusa disctrict court_EN_final.pdf
(402 KB)
20181213_PM_unabhängige Prüfung_EN_final.pdf
(144 KB)
20181126_Conference Participation_EN.pdf
(234 KB)
20181116_Q3 2018 Earnings Release_EN_final.pdf
(288 KB)
20181105_PM_Q3 Con Call Datum_EN_final.pdf
(233 KB)
20181015_ Dawson James 2018 Conference_EN_final.pdf
(670 KB)
20181001_PM_Tageslicht CH_EN_final.pdf
(665 KB)
20180926_PM_Patientenrekrutierung_EN_final.pdf
(653 KB)
20180924_PM_Cantor Fitzgerald Healthcare Conference_EN_final.pdf
(665 KB)
20180919_PM_Baader Investment Conference_EN_final.pdf
(667 KB)
20180917_PM_Endless Summer Umsatz_EN_final.pdf
(669 KB)
20180831_Biofrontera 2Q18 Earnings Release_EN_correction.pdf
(730 KB)
20180831_ 2Q18 Earnings Release_EN.pdf
(738 KB)
20180830_PM_HJConCallReminder_EN.pdf
(668 KB)
20180816_PM_VA contract award_EN_final.pdf
(671 KB)
20180815_PM_HJ Con Call Datum_EN_final.pdf
(668 KB)
20180802_PM_Balaton Offer US_EN_final.pdf
(667 KB)
20180730_PM_2nd joint opinion_DBB_EN.pdf
(676 KB)
20180726_PM_Patientenrekrutierung_EN.pdf
(127 KB)
20180713_AGM_EN.pdf
(119 KB)
20180712_DUSA_PM_EN.pdf
(117 KB)
20180710_PM_Biofrontera on Collaboration_EN.pdf
(117 KB)
20180706_FreiwilligePrüfung_EN.pdf
(150 KB)
20180705_PR_HJ1 results_EN.pdf
(119 KB)
20180612_lawsuit_DB_EN.pdf
(107 KB)
20180611_Jointopinion_DBBAG_EN.pdf
(114 KB)
20180530_PM Balaton offer_EN.pdf
(116 KB)
20180530_ 1stQEarningsRelease_EN.pdf
(142 KB)
20180529_PRSalesforce_UK_EN.pdf
(44 KB)
20180522_Telco_1Q_EN.pdf
(40 KB)
20180430_PR2017Annualresult_EN.pdf
(146 KB)
20180426 PR Balaton offer_EN.pdf
(40 KB)
20180419_Telco_AR_EN.pdf
(39 KB)
20180315_RückzahlungWSV_EN.pdf
(59 KB)
20180315_BezugspreiseWSV_EN.pdf
(45 KB)
20180228_PR_BCC_ReimbursementScotland_EN.pdf
(41 KB)
20180216 PR Closing ADR_EN.pdf
(47 KB)
20180122_2017_RevenuePre_EN.pdf
(91 KB)
2017
2017
01/30/2017 Biofrontera Launches New U.S. Website and increases sales force to Support Launch and Commercialization of Ameluz®
(101 KB)
02/08/2017 Biofrontera adds body cream to belixos® dermo-cosmetics series
(97 KB)
02/28/2017 Biofrontera to Present at Cowen and Company's 37th Annual Healthcare Conference
(49 KB)
03/13/2017 Biofrontera Reports Detailed Phase III Results for Ameluz® in Combination with Daylight-PDT
(111 KB)
04/03/2017 Notice of Annual Results 2016
(33 KB)
04/06/2017 Biofrontera Reports Full Year 2016 Financial Results
(255 KB)
05/08/2017 Notice of first quarterly report of 2017
(32 KB)
05/19/2017 Biofrontera Reports First Quarter 2017 Financial Results
(219 KB)
05/19/2017 EIB grants financing to Biofrontera
(115 KB)
05/30/2017 Biofrontera to Present at the 2017 Marcum Microcap Conference
(97 KB)
06/12/2017 Biofrontera Files Label Extension for Ameluz® in EU to include Treatment with Daylight-PDT for Actinic Keratosis
(241 KB)
08/02/2017 Ameluz® launch for Actinic Keratosis in Israel
(42 KB)
08/04/2017 Biofrontera Agrees with U.S. FDA on Ameluz® Development Plan to Treat Basal Cell Carcinoma
(121 KB)
08/09/2017 Biofrontera strengthens its U.S. sales support services
(417 KB)
08/21/2017 Advanced notice of conference calls on half-year report of 2017
(35 KB)
08/30/2017 Biofrontera to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
(112 KB)
08/31/2017 Biofrontera Grows Revenues and Improves Financial Position in First Half 2017
(112 KB)
09/28/2017 Biofrontera Strengthens U.S. Team with Appointment of Jeffrey Holm as Vice President of Marketing
(38 KB)
10/09/2017 Biofrontera’s Ameluz® and BF-RhodoLED® Listed on the U.S. VA Federal Supply Schedule
(38 KB)
10/16/2017 Biofrontera to Present at the McGuire Woods 9th Annual Pharmaceutical and Medical Device Conference
(35 KB)
10/18/2017 Biofrontera achieves strong U.S. sales performance of Ameluz® in first year of commercialization
(47 KB)
11/10/2017 CMS issues new reimbursement codes for Ameluz® and for Photodynamic Therapy
(48 KB)
11/20/2017 Biofrontera Announces Conference Call to Discuss Third Quarter 2017 Financial Results
(40 KB)
11/26/2017 Biofrontera Reports Financial Results for Third Quarter and First Nine Months of 2017
(133 KB)
12/04/2017 Biofrontera to Present at the 10th Annual LD Micro Main Event
(278 KB)
12/19/2017 Biofrontera Files Investigational New Drug Application
(272 KB)
2016
2016
01/26/2016 FDA completes Biofrontera’s Ameluz® NDA mid-cycle review
(151 KB)
02/11/2016 Data from pivotal Phase III studies with BF-200 ALA: First introduction to US dermatologists as a poster and two oral presentations at the 14th South Beach Symposium
(199 KB)
03/04/2016 Biofrontera announces full results of Phase III clinical trial evaluating BF-200 ALA for treatment of basal cell carcinoma (BCC)
(207 KB)
03/31/2016 Swiss compulsory health insurance reimburses Ameluz® for treatment of actinic keratosis
(196 KB)
04/04/2016 Biofrontera Announces NDA Progress Update for BF-200 ALA
(246 KB)
04/07/2016 Notice of Annual Results 2016
(97 KB)
04/13/2016 Israel Ministry of Health Approves Biofrontera’s Ameluz® for treatment of actinic keratosis
(244 KB)
04/14/2016 Biofrontera Reports Full Year 2015 Financial Results
(201 KB)
04/28/2016 Announcement of adjustment of the option price of warrants
(252 KB)
05/11/2016 Biofrontera Announces U.S. FDA Approval of Ameluz® and Activating BF-RhodoLED® Device for Treatment of Actinic Keratosis
(253 KB)
05/23/2016 Notice of quarterly report of 2016
(98 KB)
05/25/2016 Biofrontera Reports First Quarter 2016 Financial Results and Business Update
(268 KB)
06/02/2016 Biofrontera Announces Appointment of Four New Supervisory Board Members
(251 KB)
06/23/2016 Biofrontera Progresses with Expansion of U.S. Subsidiary with Key Personnel Hires
(198 KB)
06/30/2016 Biofrontera Initiates Phase III Trial of Ameluz® in Combination with Daylight-PDT
(301 KB)
07/08/2016 Biofrontera Expands belixos® Dermo-Cosmetics Product Line with belixos® To Go
(292 KB)
07/25/2016 Biofrontera to Present at the Canaccord Genuity Annual Growth Conference
(96 KB)
08/25/2016 Biofrontera Accelerates Production of BF-RhodoLED® Lamps to Prepare for U.S. Commercial Launch
(41 KB)
08/25/2016 Notice of half-year report of 2016
(33 KB)
08/29/2016 Biofrontera to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
(33 KB)
08/30/2016 Biofrontera Reports Financial Results and Business Update for Second Quarter and First Half 2016
(90 KB)
09/16/2016 Biofrontera Receives Label Expansion for Ameluz® in Europe to Include Field Cancerization
(179 KB)
09/19/2016 Biofrontera Completes Patient Recruitment of Phase III Trial of Ameluz® in Combination with Daylight-PDT
(79 KB)
10/07/2016 Biofrontera to Present at the Dawson James Securities 2nd Annual Growth Stock Conference
(106 KB)
10/18/2016 Biofrontera Initiates U.S. Commercial Launch of Ameluz® for Actinic Keratosis
(208 KB)
10/20/2016 Biofrontera Announces 12-Month Follow-Up Results of Phase III Trial Evaluating Ameluz® for Basal Cell Carcinoma
(114 KB)
07/28/2016 Biofrontera Receives Favourable CHMP Assessment for Field-Directed Therapy and Files BCC Application
(54 KB)
11/24/2016 Notice of 3rd quarterly report 2016
(33 KB)
11/28/2016 Biofrontera Reports Financial Results and Business Update for Third Quarter and First Nine Months 2016
(90 KB)
11/28/2016 European Commission provides unlimited approval for Ameluz®
(72 KB)
11/30/2016 Biofrontera to Present at the 9th Annual LD Micro Main Event
(33 KB)
12/20/2016 European Medicines Agency recommends indication expansion of Ameluz® for treatment of basal cell carcinoma (BCC)
(136 KB)
2015
2015
01/22/2015 Biofrontera AG selects designated sponsor in Germany
(85 KB)
01/26/2015 Biofrontera prepares market launch in Belgium for its non-melanoma skin cancer drug Ameluz®
(100 KB)
03/24/2015 Biofrontera starts Sales and Marketing of Ameluz® in Spain
(156 KB)
03/29/2015 Notice of Annual Results 2014
(85 KB)
04/08/2015 Biofrontera stabilizes shareholder structure
(100 KB)
04/09/2015 Biofrontera significantly increases its turnover in Germany in 2014
(107 KB)
04/16/2015 Biofrontera starts with robust growth into the new year
(110 KB)
04/19/2015 Biofrontera establishes subsidiary in the US
(145 KB)
05/06/2015 Biofrontera delivers excellent results from the Phase III study for field therapy of actinic keratosis for publication
(108 KB)
05/22/2015 Notice of First Quarter Results 2015
(75 KB)
05/29/2015 Biofrontera delivers strong performance for Q1 2015
(113 KB)
06/22/2015 Biofrontera completes final steps ahead of FDA New Drug Application in the USA
(111 KB)
07/13/2015 Biofrontera submits New Drug Application for Ameluz® to FDA
(169 KB)
07/16/2015 Biofrontera launches ‘Belixos® Protect’, a daily skincare product for sun-damaged skin
(140 KB)
07/22/2015 Biofrontera appoints Christoph Dünwald as Chief Commercial Officer
(111 KB)
08/07/2015 Biofrontera AG Notice of First Half Year Results 2015
(86 KB)
08/13/2015 Biofrontera progresses well in first half year 2015
(107 KB)
31/08/2015 Biofrontera - Result of Annual General Meeting
(94 KB)
09/21/2015 Excellent long-term outcome with field treatment of actinic keratosis with Ameluz®
(92 KB)
10/01/2015 FDA determines May 10, 2016 as PDUFA* date for Ameluz®
(133 KB)
11/11/2015 Biofrontera's business operations on track
(128 KB)
11/12/2015 Biofrontera AG Notice of Third Quarter Results 2015
(76 KB)
11/19/2015 Biofrontera reports final patient visit in phase III trial for basal cell carcinoma
(78 KB)
11/20/2015 Q3 Results well on track
(129 KB)
12/07/2015 Swissmedic grants marketing approval for Ameluz® in Switzerland
(79 KB)
12/13/2015 FDA grants small business waiver
(97 KB)
2014
2014
02/21/2014 Belixos® - nature‘s best to nurture your skin! Social media campaign started02/21/2014 Belixos® - nature‘s best to nurture your skin! Social media campaign started
(207 KB)
02/27/2014 Biofrontera expands the Belixos® cosmeceutical product series
(190 KB)
03/26/2014 Biofrontera publishes financial report 2013
(217 KB)
05/19/2014 Biofrontera AG publishes 1st quarter 2014 interim report
(218 KB)
07/02/2014 PDT with Ameluz® is the most efficacious treatment option for actinic keratosis
(78 KB)
08/06/2014 First Ameluz® sales in Central Eastern European region
(127 KB)
08/11/2014 Ameluz® has passed first stage in approval process in Israel
(89 KB)
08/18/2014 Belixos® now available through Amazon in Germany and UK
(123 KB)
08/21/2014 Pre-NDA meeting scheduled with FDA for the approval of Ameluz® and BF-RhodoLED®
(133 KB)
08/29/2014 Half Year Results: Progress in business operations
(256 KB)
11/11/2014 Biofrontera AG hosts conference call on 13 November 2014 to present results of the 3rd quarter 2014
(100 KB)
11/13/2014 Biofrontera publishes report on the third quarter of 2014
(113 KB)
11/25/2014 Further progress in international approval processes of Biofrontera’s Ameluz®
(151 KB)
12/05/2014 Biofrontera launches new addition Belixos® Gel to its derma-cosmetic line
(97 KB)
2013
2013
01/08/2013 Biofrontera receives positive EMA opinion on extended storage conditions for Ameluz®
(91 KB)
03/12/2013 Biofrontera explains corporate strategy and clinical development program in telephone conference
(85 KB)
03/25/2013 Maschmeyer increases share holding in Biofrontera AG
(79 KB)
04/11/ 2013 Biofrontera AG to host conference call on 15 April 2013 to present results of the fiscal year 2012
(140 KB)
04/15/2013 Biofrontera AG publishes financial results for 2012
(101 KB)
05/17/2013 Biofrontera publishes 1st quarter 2013 interim report
(226 KB)
06/04/2013 Biofrontera AG appoints Thomas Schaffer as CFO
(89 KB)
06/10/2013 Biofrontera AG with new Corporate Website
(81 KB)
08/01/2013 Biofrontera AG appoints M.M.Warburg & CO as new Designated Sponsor
(164 KB)
08/23/2013 Biofrontera AG reports half-year financial results for 2013
(79 KB)
09/06/2013 Biofrontera announces brokerage agreement and research coverage with finnCap
(79 KB)
09/20/2013 Actinic keratosis, most efficiently treated by Ameluz®, recognized as occupational disease
(169 KB)
10/14/2013 Patient recruitment started in phase III study for field-therapy of actinic keratosis
(89 KB)
10/21/2013 Allergan launches Ameluz® in Spain
(101 KB)
11/08/2013 Biofrontera publishes interim report for the 3rd quarter of 2013
(90 KB)
12/12/2013 All Wales Medicine Strategy Group recommends the use of Ameluz®
(88 KB)